NASDAQ:IOVA

Iovance Biotherapeutics - IOVA Stock Forecast, Price & News

$6.84

+0.43 (+6.71%)

(As of 12/2/2022 12:00 AM ET)

Add

Compare

Today's Range: $6.28
▼
$6.89
50-Day Range: $5.95
▼
$10.24
52-Week Range: $5.42
▼
$20.60

Volume: 14.07 million shs
Average Volume: 4.03 million shs
Market Capitalization: $1.08 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.40

Iovance Biotherapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.73 Rating Score
Upside/Downside: 227.5% Upside
$22.40 Price Target
Short Interest: Healthy
12.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.95
Upright™ Environmental Score
News Sentiment: 0.86
Based on 12 Articles This Week
Insider Trading: Acquiring Shares
$65.13 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.50) to ($2.44) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

74th out of 1,034 stocks

Biological Products, Except Diagnostic Industry

11th out of 171 stocks

4.4

Analyst's Opinion

Consensus Rating
Iovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.40, Iovance Biotherapeutics has a forecasted upside of 227.5% from its current price of $6.84.
Amount of Analyst Coverage
Iovance Biotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
12.20% of the float of Iovance Biotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
Iovance Biotherapeutics has a short interest ratio ("days to cover") of 8.
Change versus previous month
Short interest in Iovance Biotherapeutics has recently decreased by 5.01%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Iovance Biotherapeutics does not currently pay a dividend.
Dividend Growth
Iovance Biotherapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Iovance Biotherapeutics has received a 72.72% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.
Environmental Sustainability
The Environmental Impact score for Iovance Biotherapeutics is -0.95.

3.3

News and Social Media Coverage

News Sentiment
Iovance Biotherapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.30 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Iovance Biotherapeutics this week, compared to 1 article on an average week.
Search Interest
20 people have searched for IOVA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Iovance Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $65,128,780.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.60% of the stock of Iovance Biotherapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($2.50) to ($2.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Iovance Biotherapeutics is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Iovance Biotherapeutics is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Iovance Biotherapeutics has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Stock News Headlines

December 1, 2022 | benzinga.com

63K Reasons To Be Bullish On Iovance Biotherapeutics Stock

December 1, 2022 | americanbankingnews.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Director Merrill A. Mcpeak Buys 10,000 Shares

December 1, 2022 | americanbankingnews.com

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Up on Insider Buying Activity

November 30, 2022 | americanbankingnews.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Director Iain D. Dukes Buys 10,000 Shares

November 29, 2022 | benzinga.com

Iovance Biotherapeutics Recent Insider Activity

November 24, 2022 | americanbankingnews.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Moderate Buy" by Brokerages

November 21, 2022 | markets.businessinsider.com

JMP Securities Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)

November 18, 2022 | markets.businessinsider.com

Iovance Declines Following FDA Feedback On Its Melanoma Drug Lifileucel

November 18, 2022 | markets.businessinsider.com

Robert W. Baird Keeps Their Buy Rating on SAB Biotherapeutics (SABS)

November 4, 2022 | msn.com

Recap: Iovance Biotherapeutics Q3 Earnings

November 2, 2022 | msn.com

Preview: Iovance Biotherapeutics's Earnings

October 10, 2022 | finance.yahoo.com

Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy

September 27, 2022 | seekingalpha.com

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

September 10, 2022 | seekingalpha.com

IOVA Iovance Biotherapeutics, Inc.

September 6, 2022 | finance.yahoo.com

Iovance Biotherapeutics to Present Posters at ESMO 2022

September 5, 2022 | americanbankingnews.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Rating of "Moderate Buy" from Analysts

September 5, 2022 | msn.com

As Philly becomes a hub for life sciences, a new program will train workers for jobs in the field

August 25, 2022 | finance.yahoo.com

Biomedical technician training program launches to support Philadelphia's growing life sciences sector

August 6, 2022 | seekingalpha.com

Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss

August 5, 2022 | markets.businessinsider.com

Expert Ratings for Iovance Biotherapeutics

August 5, 2022 | nasdaq.com

Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track

August 5, 2022 | seekingalpha.com

Iovance Biotherapeutics, Inc. (IOVA) CEO Fred Vogt on Q2 2022 Results - Earnings Call Transcript

July 12, 2022 | seekingalpha.com

Iovance: TIL Cell Therapy Set To Prove Itself

July 1, 2022 | markets.businessinsider.com

7 Analysts Have This to Say About Iovance Biotherapeutics

June 13, 2022 | finance.yahoo.com

Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Company Calendar

Last Earnings: 11/04/2021
Today: 12/03/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/23/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IOVA
CUSIP: N/A
CIK: 1425205
Web: www.iovance.com
Phone: (650) 260-7120
Fax: N/A
Employees: 319
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $22.40
High Stock Price Forecast: $38.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +227.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.73
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-342,250,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -76.45%
Return on Assets: -59.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.67
Quick Ratio: 4.67

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.49 per share
Price / Book: 2.75

Miscellaneous

Outstanding Shares: 157,840,000
Free Float: 145,845,000
Market Cap: $1.08 billion
Optionable: Optionable
Beta: 0.38

Key Executives

Dr. Frederick G. Vogt Esq. (Age 48)
J.D., Ph.D., Interim CEO, Pres, Gen. Counsel & Corp. Sec.
Comp: $752.81k

Mr. Jean-Marc Bellemin M.B.A. (Age 50)
Chief Financial Officer & Principal Accounting Officer
Comp: $623.6k

Dr. Igor P. Bilinsky (Age 49)
Chief Operating Officer
Comp: $577.35k

Dr. Friedrich Graf Finckenstein M.D. (Age 55)
Chief Medical Officer
Comp: $649.13k

Ms. Sara Pellegrino
VP of Investor Relations & PR

Ms. Tracy Winton
Sr. VP of HR

Mr. Howard B. Johnson M.B.A. (Age 62)
Chief Bus. Officer

Mr. James Ziegler M.B.A.
Exec. VP of Commercial

Mr. Madan Jagasia
Exec. VP of Medical Affairs

Dr. Raj K. Puri M.D.
Ph.D., Exec. VP of Regulatory Strategy & Translational Medicine

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IOVA Stock - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings or view top-rated stocks.
What is Iovance Biotherapeutics' stock price forecast for 2023?: 11 Wall Street research analysts have issued 1 year price objectives for Iovance Biotherapeutics' stock. Their IOVA share price forecasts range from $11.00 to $38.00. On average, they expect the company's stock price to reach $22.40 in the next twelve months. This suggests a possible upside of 227.5% from the stock's current price.
View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts.
How have IOVA shares performed in 2022?: Iovance Biotherapeutics' stock was trading at $19.09 on January 1st, 2022. Since then, IOVA stock has decreased by 64.2% and is now trading at $6.84.
View the best growth stocks for 2022 here.
When is Iovance Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our IOVA earnings forecast.
How were Iovance Biotherapeutics' earnings last quarter?: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) released its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.02. During the same period in the prior year, the company earned ($0.40) earnings per share.
What other stocks do shareholders of Iovance Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?: Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."
Who are Iovance Biotherapeutics' major shareholders?: Iovance Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.03%), BlackRock Inc. (7.26%), Perceptive Advisors LLC (6.49%), State Street Corp (6.29%), Price T Rowe Associates Inc. MD (2.98%) and Pictet Asset Management SA (2.52%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends.
How do I buy shares of Iovance Biotherapeutics?: Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Iovance Biotherapeutics' stock price today?: One share of IOVA stock can currently be purchased for approximately $6.84.
How much money does Iovance Biotherapeutics make?: Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.08 billion. The biotechnology company earns $-342,250,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.
How many employees does Iovance Biotherapeutics have?: The company employs 319 workers across the globe.
How can I contact Iovance Biotherapeutics?: Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.

This page (NASDAQ:IOVA) was last updated on 12/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Iovance Biotherapeutics - IOVA Stock Forecast, Price & News

Iovance Biotherapeutics MarketRank™ Forecast

Overall MarketRank™